Literature DB >> 1066118

[Treatment and prognosis of osteosarcoma in childhood (author's transl)].

M Salzer, M Salzer-Kuntschik, K Zhuber, C H Price, H G Willert, M Immenkamp, Z Matejovsky, P Groh, W Keyl.   

Abstract

126 osteosarcoma under the age of 15 years are followed up in an interclinical study. There is a steady increase of tumor incidence towards the 15th year with a slight male preponderance. The main sites of the tumor are the distal femur followed by the proximal tibia and humerus. Evidence of multiple metastases is most often present in the lungs, less often in the skeleton. Nearly always metastases became evident within 2 1/2 years after diagnosis (98%). Therefore the 2 1/2-year disease--free survival rate seems to be sufficient for prognostic evaluation. The over all 2 1/2-year survival rate was 17,5%. Though the different methods of treatment are not statistically valid, the best results can be expected after early amputation. By radiotherapy alone no cure has been achieved. Survivals were seen at any age and at any site of long bones (distal femur, proximal tibia, humerus, femur, distal radius). Prognosis of osteosarcoma in the childhood is similar to that of the adult group.

Entities:  

Mesh:

Year:  1976        PMID: 1066118     DOI: 10.1007/bf00415190

Source DB:  PubMed          Journal:  Arch Orthop Unfallchir        ISSN: 0003-9330


  18 in total

1.  Osteogenic sarcoma in children.

Authors:  A B HAYLES; D C DAHLIN; M B COVENTRY
Journal:  JAMA       Date:  1960-10-29       Impact factor: 56.272

2.  Osteosarcoma. A review of 96 cases.

Authors:  A LINDBOM; G SODERBERG; H J SPJUT
Journal:  Acta radiol       Date:  1961-07       Impact factor: 1.990

3.  Osteogenic sarcoma; a critical analysis of 430 cases.

Authors:  M B COVENTRY; D C DAHLIN
Journal:  J Bone Joint Surg Am       Date:  1957-07       Impact factor: 5.284

4.  [Osteosarcoma in childhood].

Authors:  Z Matĕjovský; C H Price; K Zhuber; M Salzer-Kuntschik; M Salzer; H G Willert; M Immenkamp; P Groh; W Keyl
Journal:  Acta Chir Orthop Traumatol Cech       Date:  1975-08       Impact factor: 0.531

5.  Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.

Authors:  N Jaffe; E Frei; D Traggis; Y Bishop
Journal:  N Engl J Med       Date:  1974-11-07       Impact factor: 91.245

6.  High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.

Authors:  G Rosen; S Suwansirikul; C Kwon; C Tan; S J Wu; E J Beattie; M L Murphy
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

7.  Amputation and adriamycin in primary osteosarcoma.

Authors:  E P Cortes; J F Holland; J J Wang; L F Sinks; J Blom; H Senn; A Bank; O Glidewell
Journal:  N Engl J Med       Date:  1974-11-07       Impact factor: 91.245

8.  Therapy and prognosis of the Ewing-sarcoma.

Authors:  R Kotz; M Salzer-Kuntschik; K Zweymüller; M Salzer
Journal:  Osterr Z Onkol       Date:  1974

9.  [Malignant bone tumors in childhood].

Authors:  F Kuffer; H P Wagner; J Laissue
Journal:  Schweiz Rundsch Med Prax       Date:  1970-09-22

10.  Metastatic spread of osteosarcoma.

Authors:  C H Price; G M Jeffree
Journal:  Br J Cancer       Date:  1973-12       Impact factor: 7.640

View more
  2 in total

Review 1.  Interferons: anti-neoplastic drugs?

Authors:  H Strander
Journal:  Blut       Date:  1977-09-18

2.  Possibilities and limitations of limb-preserving therapy for bone tumors today.

Authors:  R Kotz
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.